Novartis in AMD deal

May 2014
Optometry Today;5/23/2014, Vol. 54 Issue 10, p5
The article reports on a licensing agreement between pharmaceutical companies Novartis and Ophthotech concerning the non-U.S. commercial rights to Novartis' wet age-related macular degeneration (AMD) drug Fovista.


Related Articles

  • Deal watch: Novartis eyes vision-enhancing therapy for macular degeneration. Cully, Megan // Nature Reviews Drug Discovery;Jul2014, Vol. 13 Issue 7, p487 

    The article reports on the acquisition of the non-U.S. rights to the aptamer-based therapy for wet age-related macular degeneration (AMD), Fovista, of Ophthotech Corp. by the pharmaceutical company Novartis AG.

  • OPHTHOTECH. Investor's Business Daily // Investors Business Daily;5/20/2014, pA02 

    The article reports that biotechnology company Ophthotech licensed its Fovista macular degeneration drug to pharmaceutical company Novartis AG and mentions the increase of Ophthotech's shares and decline in Novartis' shares.

  • Tech startup of the month. Peterson, Eric // ColoradoBiz;May2002, Vol. 29 Issue 5, p49 

    Features the GlobeImmune Inc. in Denver, Colorado. Production of vaccine from brewer's yeast proteins; Focus on the HIV disease; Licensing agreement with Novartis.

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/7/2010, Vol. 21 Issue 108, p6 

    This section offers news briefs concerning the biotechnology industries, which include the licensing agreement between Ascalon International Inc. and CerRx Inc., the agreement between Emisphere Technologies Inc. and Novartis AG and preclinical data on the dual agonist of Toll-like Receptor 7...

  • Agricultural biotechnology. Fairley, Peter // Chemical Week;7/22/1998, Vol. 160 Issue 27, p16 

    Reports on the expansion of the 1993 cross-licensing agreement between Novartis and Dow subsidiary Mycogen. Coverage of the licensing agreement; Products to be marketed by the companies; Comments from Michael Muston, president of Mycogen's seeds unit.

  • Debiopharm signs licensing agreement with Novartis.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p16 

    The article reports that Swiss biopharmaceutical firm Debiopharm Group has signed a licensing agreement with Novartis AG for the commercialization, manufacture and development of Debio 025, a selective, cyclophilin inhibitor with a potent antihepatitis C virus (HCV) effect.

  • Novartis Acquires Hepatitis C Franchise.  // Chemical Market Reporter;3/31/2003, Vol. 263 Issue 13, p2 

    Focuses on the stakes acquired by Novartis AG from biotechnology company Indenix in Cambridge, Massachusetts. Terms of the deal; Payments made for the licensing of hepatitis drugs.

  • Novartis' Lens Effect.  // Micro Mart;7/24/2014, Issue 1321, p37 

    The article reports that Internet search company Google and Swiss company Novartis have signed an agreement allowing to license Google X Labs' smart lens technology.

  • University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy.  // Biomedical Market Newsletter;8/1/2012, Vol. 21, p1 

    The article informs that the University of Pennsylvania, Philadelphia, Pennsylvania and Novartis AG have announced an exclusive global research and licensing agreement to study and commercialize novel cellular immunotherapies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics